These survey results indicate that young adults tended to embrace misconceptions regarding sun protection and positive views of tanning.

Patients often rely on opioids a year before and a year after a diagnosis of ankylosing spondylitis, psoriatic arthritis, or rheumatoid arthritis.

Findings suggest metformin and statins have a potective effect against HCC in patients with HCV who fail antiviral therapy.

Our April month in review for hematology breaks down the latest updates to the pipeline, mortality risk in people with sickle cell disease, and our newest multimedia offerings.

The April 2024 cardiology month in review spotlights FDA news and top updates from the American College of Cardiology 2024 Scientific Session.

At 6 months, patients treated with ReNu exhibited significant reductions in assessed knee pain and maintained patient function compared with controls.

These data suggest vaping poses potential threats to the development of the brain and organs, with teenagers being a predominant target due to surges in use.

Experts discuss treating dry eye with procedural therapies, focusing on common in-office and at-home treatments.

A new study found specific sociodemographic factors were linked to 76.4% lower odds of adhering to topical therapy for psoriasis.

This month in review highlights top coverage of the latest news in nephrology, ranging from new clinical trial data in IgAN to research about kidney disease management.

This month's review showcases the ongoing efforts to enhance patient care through innovative treatments and comprehensive management strategies.

An interim analysis of a phase 3 trial displays the effectiveness of prophylaxis with recombinant ADAMTS13, achieving approximately 100% of normal ADAMTS13 levels.

In this review of April 2024, the editorial team highlighted some of the biggest stories in the pulmonary health space, touching on topics such as air quality issues, asthma, and pneumonia.

Key opinion leaders in cardiology share insights on reducing LDL cholesterol to manage cardiovascular disease risk, educating patients not reaching goals, and implementing real-world clinical strategies for maintaining lower LDL levels.

Erin Michos, MD, delivers a comprehensive review of lipid management and its influence on cardiovascular disease, emphasizing recent studies that underscore the need for improved treatment strategies for high-risk patients.

This sleep month in review features positive pipeline updates and treatments for improved sleep quality.

Urinary cytokines GDF-15, IL-6, and EGF significantly strengthened the predictability of IgAN prognosis and may be viable biomarker candidates for disease progression.

An analysis of NHANES found aspirin's benefits in primary prevention may hinge on lipoprotein(a) (Lp(a)) levels, halving ASCVD mortality risk with Lp(a) ≥50 mg/dL.

FDA approves label update for voclosporin (Lupkynis) in lupus nephritis, reflecting long-term AURORA data and new kidney function monitoring guidance.

An analysis of the NIH's All of Us program finds no increased ILD risk with methotrexate in dermatomyositis.

Implementation of an artificial intelligence-enabled ECG reduced the risk of all-cause mortality within 90 days among hospitalized patients.

The current approval is based on the VOLTAIRE-HCLF clinical trial, which examined the bioavailability of high-concentration (100 mg/mL) and low-concentration (50 mg/mL) formulations of adalimumab-adbm.

In this review of dermatology news in April, we highlighted several major stories on such topics as cutaneous reactions to COVID-19, topical versus oral minoxidil, and FDA news.

This month in review features top psychiatry news in the pipeline, FDA approvals, and a piece for autism awareness month.

The April 2024 month in review features HCPLive’s top coverage of resmetirom, other key hepatic pipeline updates, and recent research about hepatitis C virus.